Editorial
Published on 11 Mar 2025
Editorial: Metabolic reprogramming in cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1583986
- 492 views
Type at least 3 characters
2,799 articles
Original Research
Published on 11 Mar 2025
Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1519849
- 905 views
Original Research
Published on 11 Mar 2025
Gut microbiota-derived metabolite phenylacetylglutamine inhibits the progression of prostate cancer by suppressing the Wnt/β-catenin signaling pathway
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1528058
- 823 views
Case Report
Published on 10 Mar 2025
Case Report: A novel MET exon 14 skipping mutation after EGFR-TKI resistance in advanced lung adenocarcinoma and sustained clinical response to savolitinib
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1489696
- 544 views
Review
Published on 10 Mar 2025
TCR-T cell therapy for solid tumors: challenges and emerging solutions
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1493346
- 1,199 views
Review
Accepted on 04 Mar 2025
Current Paradigm and Futuristic Vision on New-onset Diabetes and Pancreatic Cancer Research
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1543112
- 114 views
Systematic Review
Published on 03 Mar 2025
Comparison of efficacy and safety of adjuvant therapies versus sorafenib in hepatocellular carcinoma: a systematic review and network meta-analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1502931
- 1,062 views
Original Research
Published on 03 Mar 2025
Multi-omics analysis of the dynamic role of STAR+ cells in regulating platinum-based chemotherapy responses and tumor microenvironment in serous ovarian carcinoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1545762
- 856 views
Review
Published on 03 Mar 2025
The multiple biological activities of hyperoside: from molecular mechanisms to therapeutic perspectives in neoplastic and non-neoplastic diseases
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1538601
- 951 views
Original Research
Published on 28 Feb 2025
Dehydrodiisoeugenol targets the PLK1-p53 axis to inhibit breast cancer cell cycle
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1545498
- 816 views
Original Research
Published on 28 Feb 2025
Repurposing hydrochlorothiazide (HCTZ) for colorectal cancer: a retrospective and single center study
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1449062
- 488 views
Mini Review
Published on 28 Feb 2025
Research progress on ferroptosis in Myelodysplastic syndromes
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1561072
- 912 views
Original Research
Published on 26 Feb 2025
Small molecule inhibition of ubiquitin C-terminal hydrolase L1 alters cell metabolism proteins and exerts anti- or pro-tumorigenic effects contingent upon chemosensitivity status in high grade serous ovarian cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1547164
- 696 views
Review
Published on 26 Feb 2025
Unleashing the power of peptides in prostate cancer immunotherapy: mechanism, facts and perspectives
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1478331
- 1,708 views
Original Research
Published on 26 Feb 2025
Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1481114
- 1,330 views
Review
Published on 26 Feb 2025
Mitochondria-associated non-coding RNAs and their impact on drug resistance
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1472804
- 883 views